Patient-reported outcomes after surgery or radiotherapy for localised prostate cancer: a retrospective study

Ng, Chye Yew; Kong, KY; Li, C-Y; Li, Jennifer Kt; Li, NY; Ng, Brian; Leung, Shing-Chi; Hong, Cindy Yl; Yee, Caitlin; Teoh, Jeremy Yuen‐Chun

doi:10.12809/hkmj198239

Cited by 6 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifth, although the final models were adjusted for sociodemographic and baseline characteristics, there may be residual confounding due to unmeasured covariates, for example previous medical and surgical histories, which are likely to differ between treatment groups. Finally, while most of our findings are in line with previous population-based studies [ 3 – 6 , 33 , 34 ], the lack of consistency in the treatment approaches compared, PROMs measurement tools used, differences in follow-up periods, and the outcomes studied limits our ability to compare our results directly with other PROMs research [ 7 , 8 ]. It should be highlighted that our findings are based on ‘real world data’, and as such, reflect the actual experiences of men during their prostate cancer journey.…”

Section: Discussionsupporting

confidence: 72%

Patient-reported functional outcome measures and treatment choice for prostate cancer

et al. 2022

View full text Add to dashboard Cite

Background The aim of this study was to describe changes in patient-reported functional outcome measures (PROMs) comparing pre-treatment and 12 months after radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy and active surveillance (AS). Methods Men enrolled from 2010 to 2019 in the South Australian Prostate Cancer Clinical Outcomes Collaborative registry a prospective clinical registry were studied. Urinary, bowel, and sexual functions were measured using Expanded Prostate Cancer Index Composite (EPIC-26) at baseline and 12 months post-treatment. Higher scores on the EPIC-26 indicate better function. Multivariable regression models were applied to compare differences in function and extent of bother by treatment. Results Of the 4926 eligible men, 57.0% underwent RP, 20.5% EBRT, 7.0% brachytherapy and 15.5% AS. While baseline urinary and bowel function varied little across treatment groups, sexual function differed greatly (adjusted mean scores: RP = 56.3, EBRT = 45.8, brachytherapy = 61.4, AS = 52.8; p < 0.001). Post-treatment urinary continence and sexual function declined in all treatment groups, with the greatest decline for sexual function after RP (adjusted mean score change − 28.9). After adjustment for baseline differences, post-treatment sexual function scores after EBRT (6.4; 95%CI, 0.9–12.0) and brachytherapy (17.4; 95%CI, 9.4–25.5) were higher than after RP. Likewise, urinary continence after EBRT (13.6; 95%CI, 9.0-18.2), brachytherapy (10.6; 95%CI, 3.9–17.3) and AS (10.6; 95%CI, 5.9–15.3) were higher than after RP. Conversely, EBRT was associated with lower bowel function (− 7.9; 95%CI, − 12.4 to − 3.5) than RP. EBRT and AS were associated with lower odds of sexual bother (OR 0.51; 95%CI, 0.29–0.89 and OR 0.60; 95%CI, 0.38–0.96, respectively), and EBRT with higher odds of bowel bother (OR 2.01; 95%CI, 1.23–3.29) compared with RP. Conclusion The four common treatment approaches for prostate cancer were associated with different patterns of patient-reported functional outcomes, both pre- and 12 months post-treatment. However, after adjustment, RP was associated with a greater decline in urinary continence and sexual function than other treatments. This study underscores the importance of collecting baseline PROMs to interpret post-treatment functional outcomes.

show abstract

Section: Discussionsupporting

confidence: 72%

Patient-reported functional outcome measures and treatment choice for prostate cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…After excluding 2402 duplicate articles and 10,203 articles with non‐compliant titles and abstracts, 210 articles remained. Among the remaining 210 studies, 28 studies 8–11,24–47 ultimately met the inclusion criteria.…”

Section: Resultsmentioning

confidence: 99%

Effects of surgery versus radiotherapy in patients with localized prostate cancer in terms of urinary, bowel, and sexual domains

Yao

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe health‐related quality of life (HRQoL) of patients with localized prostate cancer (LPCa) after treatment mainly surgery and radiotherapy (RT) has received increasing attention. The aim of this study is to compare the HRQoL of LPCa after surgery and RT.MethodsWeb of Science, Embase, PubMed and Cochrane databases were searched after January 2000 to observe the HRQoL scores after surgery and RT at different treatment time points.ResultsA total of 28 studies were included in this study, and the results showed that LPCa received surgery had better bowel scores than RT at ≤3 (weighted mean differences [WMD] = 4.18; p = 0.03), 3–6 (WMD = 4.16; p < 0.001), 6–12 (WMD = 2.99; p = 0.004), 24–60 (WMD = 1.87; p = 0.06), and ≥60 (WMD = 4.54; p = 0.02) months. However, LPCa received RT had higher urinary scores at ≤3 (WMD = −7.39; p = 0.02), 3–6 (WMD = −6.03; p = 0.02), 6–12 (WMD = −4.90; p < 0.001), 24–60 (WMD = −3.96; p < 0.001), ≥60 (WMD = −2.95; p < 0.001) months and had better sexual scores at ≤3 (WMD = −13.58; p = 0.09), 3–6 (WMD = −12.32; p = 0.06), 6–12 (WMD = −12.03; p = 0.002), 24–60 (WMD = −11.29; p < 0.001), and ≥60 (WMD = −3.10; p = 0.46) months than surgery. The scores difference between surgery and RT decreased over time.ConclusionOverall, for LPCa, surgery was associated with better HRQoL in the bowel domain, whereas RT was associated with better HRQoL in the urinary and sexual domains, with the difference between surgery and RT narrowing over time.

show abstract

“…19 In addition to clinical outcomes, patient-reported outcomes should be explored among patients with cancer. 20 Additional studies are needed regarding the long-term impact of the COVID-19 pandemic on cancer care to determine how it may affect the cancer burden in Hong Kong during the post-pandemic era.…”

Section: Implications For Cancer Care During the Pandemicmentioning

confidence: 99%

Impact of the COVID-19 pandemic on cancer care

Huang

Wang²,

Zheng

et al. 2022

Hong Kong Med J

View full text Add to dashboard Cite

Patient-reported outcomes after surgery or radiotherapy for localised prostate cancer: a retrospective study

Cited by 6 publications

References 11 publications

Patient-reported functional outcome measures and treatment choice for prostate cancer

Patient-reported functional outcome measures and treatment choice for prostate cancer

Effects of surgery versus radiotherapy in patients with localized prostate cancer in terms of urinary, bowel, and sexual domains

Impact of the COVID-19 pandemic on cancer care

Contact Info

Product

Resources

About